Lavipharm (FRA:BXA0) Research & Development: €0.34 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BXA0 Lavipharm SA FRA:BXA0
79 GF Score
Price €1.55
GF Value €1.03
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Lavipharm Research & Development?

Lavipharm FRA:BXA0 +0.78% 79 Research & Development is €0.34 Mil as of Dec. 2025. GuruFocus rates FRA:BXA0 with a GF Score™ of 79/100 and a GF Value™ of €1.03 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Lavipharm's Research & Development for the six months ended in Dec. 2025 was €0.21 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.34 Mil.

Lavipharm  (FRA:BXA0) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Lavipharm Research & Development Related Terms

Lavipharm Research & Development Historical Data

* Premium members only.

The historical data trend for Lavipharm's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lavipharm Research & Development Chart

Lavipharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 0.81 0.85 0.43 0.63 0.34

Lavipharm Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.20 0.43 0.14 0.21
FRA:BXA0
79GF Score
Lavipharm SA FRA:BXA0
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lavipharm Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.34 Mil mean?
Lavipharm (FRA:BXA0) has a Research & Development of €0.34 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Lavipharm and its competitors.
Is Lavipharm's Research & Development too high?
Lavipharm's current Research & Development is €0.34 Mil. Overall, Lavipharm has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lavipharm's Research & Development compare to ZTS and UTHR?
Lavipharm's Research & Development of €0.34 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Lavipharm and its competitors. Lavipharm's current Research & Development is €0.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lavipharm stock overvalued right now?
Based on GuruFocus' analysis, Lavipharm (FRA:BXA0) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.03, compared to a current price of €1.55 — trading 50.5% above its estimated fair value. The current Research & Development is €0.34 Mil. Lavipharm's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Lavipharm (FRA:BXA0), the current Research & Development is €0.34 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lavipharm (FRA:BXA0) Overvalued in 2026?

Based on GuruFocus' analysis, Lavipharm stock appears to be overvalued. The current stock price of €1.55 is trading 50.5% above its estimated GF Value™ of €1.03. GuruFocus considers Lavipharm to be Significantly Overvalued.

Key valuation signals for FRA:BXA0:

  • Research & Development: €0.34 Mil
  • GF Value™: €1.03 vs. price of €1.55 (50.5% above fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the FRA:BXA0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lavipharm Business Description

Other Exchanges LAVI:Greece
Address 12, Agias Marinas Street, PO Box 59, Paiania, GRC, 19002
Lavipharm SA develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumers' needs for health and well-being. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, Chronic Pain, General Medicine, Self-Treatment, and Dermocosmetic care.
79GF Score

Get the complete analysis for FRA:BXA0

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.55
Price
€1.03
GF Value